Serial Dilution in 96- & 384-well Microplates
Integra has introduced a Row Dilution Plate Holder accessory for its VIAFLO 96 and 384 handheld benchtop pipettes.
The new row dilution plate holder adds the functionality to perform serial dilutions in rows. Serial dilutions are often carried out in row format because it allows experimenters to dilute more samples (12 instead of 8 in a 96-well plate). The plate holder can easily be adapted to work with either 96 or 384 well plates.
Serial dilution of assay components is a key technique in drug discovery and life science research. In assay development, serial dilution can be used to determine appropriate concentration ranges, in secondary screening to evaluate pharmacological response, and in early ADMET studies to determine toxicological effects. The ability to accurately and reproducibly produce dilution curves is essential to improving assay throughput and quality. Serial dilutions are also regularly used in microbiology when, for instance, initial concentrations of bacteria are orders of magnitude too high to perform a plate count.
The VIAFLO 96/384 offers high sample throughput without a robot. It is a handheld bench top pipette, capable of 96- and 384-well pipetting with a choice of various pipetting heads. The VIAFLO 96 benchtop electronic pipette offers an affordable solution to increase productivity when working with microplates. It closes the gap between traditional manual pipettes and robotic systems, allowing for accurate and reproducible 96-channel pipetting. The VIAFLO 384 is a more advanced system, which can work with both 96- and 384-channel pipetting heads to maximize productivity. It features the same footprint and intuitive user concept as VIAFLO 96.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.